Q301--Long -Term Specialized Reference Laboratory for Measurable Residual Disease (MRD) detection in hematologic malignancies - Base Plus 4 9/1/26-8/31/31
Closed Pre-Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- 36C26026Q0807
- Agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Portland Vamc 3710 Nw Us Veterans Hospital Road Portland OR 97239
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
Veterans Integrated Service Network 20 (Department of Veterans Affairs) intends to solicit a specialized reference laboratory to provide Measurable Residual Disease (MRD) detection testing for hematologic malignancies under a base period plus four option years running September 1, 2026 through August 31, 2031, with responses to the sources sought notice due July 10, 2026.
The VA Portland Healthcare System's Pathology & Laboratory Medicine Service Department requires continued access to MRD testing that quantifies residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). Place of performance is Portland VAMC, 3710 NW US Veterans Hospital Road, Portland, Oregon 97239. The Network Contracting Office in Vancouver, Washington is processing the procurement. No set-aside is anticipated. Contracting Specialist Hector Gonzalez (hector.gonzalez1@va.gov) is the point of contact.
Notice text
The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies. MRD is a powerful diagnostic and prognostic tool that quantifies the presence of residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL).
Files
| File | Type | Posted |
|---|---|---|
| 36C26026Q0807_1.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Q301--Long -Term Specialized Reference Laboratory for Measurable Residual Disease (MRD) detection in hematologic malignancies - Base Plus 4 9/1/26-8/31/31 | Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Q301--Reference Laboratory Testing | Veterans Integrated Service Network 2 | No set-aside | |
| Q301--New Reference Lab Testing | Legacy VISN 15 | Veterans Integrated Service Network 15 | No set-aside | |
| Solicitation for subscription to software for pathology laboratory medicine services. | Veterans Integrated Service Network 20 | No set-aside | |
| Q301--Media Fill Testing for Clean Room Compliance - Pharmacy Base 4 years | Veterans Integrated Service Network 9 | Service-Disabled Veteran-Owned Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity